Safety and PK Study of NOV-205 to Treat Chronic HCV Who Fail Standard Therapy
NCT00372983
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
30
Enrollment
INDUSTRY
Sponsor class
Conditions
Hepatitis C
Interventions
DRUG:
NOV-205
Sponsor
Cellectar Biosciences, Inc.